URGOCLEAN AG

11 APR 13:00



CLEAN AND KILL INFECTION WITH URGOCLEAN AG



PRESENTED BY
BEN HARRISON
URGO PRODUCT SPECIALIST



SPONSORED BY

*URGO
MEDICAL
Healing people*

Infection is a burden for patients and the healthcare system



HIGH PREVALENCE:

Infection is one of the **most frequent complications** of non-healing wounds¹



COMPLICATIONS OF WOUND INFECTION¹:


- Delayed wound healing, patient anxiety, confusion and stress
- Hospitalisation, amputation and potentially death
- Delays in planned surgical interventions




INCREASED WORKLOAD AND EMOTIONALLY DRAINING FOR NHS STAFF

Fighting local infection is a priority and requires a quick and effective treatment from Day 1.





No wound, at risk or with signs of local infection, is a clean wound



To effectively fight against local infection, both the visible and hidden enemies in an infected wound need to be addressed



Fights against both the visible and UrgoClean Ag the hidden enemies in an infected wound







their reattachment

Provides complete and continuous UrgoClean Ag cleaning action due to its polyabsorbent fibres



Clinically proven complete cleaning action which removes wound debris such as slough, exudate, microbes and biofilm







Continuous cleaning action effectively UrgoClean Ag reduces the volume of exudate in infected wounds

- **75%** reduction in patients with heavy exudate¹
- **62.5%** reduction of sloughy tissue and wound debris¹
- Removes all signs of localised infection¹
- Continuous cleaning achieved for up to 7 days¹













UrgoClean Ag Clinically proven cleaning action

Reduction in sloughy tissue %





Polyabsorbent fibres scored significantly higher than fibres from CMC dressing in reduction in sloughy tissue demonstrating the superior efficacy of the polyabsorbent fibres






Fast and effective anti-biofilm action



99.99% biofilm population reduction achieved in just 24h¹



Blocks biofilm reattachment for up to **7 days**¹












Superior anti-biofilm efficacy¹ Compared to a silver containing CMC dressing (in vitro)


UrgoClean Ag demonstrated superior anti-biofilm efficacy compared to a silver containing CMC dressing, on both strains after 24h. Biofilm reduction >99.99%

On MRSA Mature Biofilm³

On P. aeruginosa Mature Biofilm³









1. Desroche N, et al (2017) Comparison of in vitro anti-biofilm activities of a new poly-absorbent dressing with a silver matrix and a silver-containing CMC dressing. Poster EWMA May 2017



Proven antimicrobial efficacy you can trust



- Fast action: from 30 minutes on main strains¹
- Works against bacterial strains resistant to antibiotics (e.g MRSA, VRE)²
- **99.99%** efficacy in just 24h²
- Restores the healing process







- 1. UrgoClean Ag. data on file, 20142
- 2. Desroche N, et al (2017) Comparison of in vitro anti-biofilm activities of a new poly-absorbent dressing with a silver matrix and a silver-containing CMC dressing. Poster EWMA May 2017



Comes with the unique TLC-Ag UrgoClean Ag technology, which allows atraumatic dressing changes





Will **not damage** newly formed tissue¹

 $oldsymbol{ol}}}}}}}}}$

Protects the surrounding skin¹



Polyamide fibres coated with elemental silver dressing







Efficacy proven in clinical trials, confirmed in real-life

Proven in clinical trials...

...confirmed in real life

analyses systematic reviews **UTAG**¹ RCT versus equivalent neutral dressings (superiority hypothesis) Venous leg ulcers presenting inflammatory signs Randomised suggesting a heavy bacterial colonization 102 patients controlled trials EARTH² RCT versus Aquacel® Venous or mixed aetiology leg ulcers 159 patients **URGOCLEAN AG³** clinical study Venous or mixed aetiology leg ulcers and pressure ulcer Non-comparative presenting inflammatory signs suggesting a heavy clinical trials bacterial colonization 37 patients **URGOCLEAN AG³** observational study 1,050 Chronic, 876 Acute and 339 Unclassified Wounds at risk or with signs of local infection 2.270 patients Cases series or studies

REFERENCES



ANTIBACTERIAL ACTIVITY TEST⁴ MRSA and *P.aeruginosa* Contact time: 24h

BROAD-SPECTRUM ANTIMICROBIAL TEST⁵

36 bacterials strains and 4 yeast strains Contact time: 30 min and 24h

ANTI-BIOFILM ACTIVITY TEST⁶

In Vitro studies

Mature 24 hours old biofilm *S. aureus* of Contact time: 1 day, 2 days, 4 days and 7 days without dressing change

COMPARATIVE ANTI-BIOFILM ACTIVITY TEST⁷

vs Aquacel® Ag+Extra Mature 24 hours old biofilm of *S. aureus* and *P. aeruginosa* Contact time: 24h

COMPARATIVE ANTI-BIOFILM ACTIVITY TEST⁸

vs Cutimed® Sorbact® Mature 24 hours old biofilm of *S. aureus* and *P. aeruginosa* Contact time: Day 2



UrgoClean Ag Real Life Clinical Evidence

- Efficacy proven in real-life study with more than 2000 patients, including 77 patients under the age of 18
- After only 2 weeks, 90.6% of the wounds treated demonstrated improvement of the healing process
- High antimicrobial efficacy and good restoration of the healing process regardless the level of slough and exudate in the wound
- Effective on all types of infected wounds and at risk of infection
- As reported by clinicians, UrgoClean Ag demonstrated better performance and efficacy compared to a silver containing CMC dressing



Use of a TLC-Ag dressing on 2270 patients with wounds at risk or with signs of local infection: an observational study

*Joachim Dissemond, 1 MD; Michael Dietlein, 2 MD; Ingo Neßeler, 3 MD Lutz Funke, 6 MD; Oliver Scheuermann, 5 MD; Elisa Becker, 6 Laetitia Thomassin, 7 PhD; Udo Möller, 6 MD; Serge Bohbot, 7 MD; Karl-Christian Münter 8 MD

*Corresponding author email: joachim.dissemond@uk-essen.de

1 Department of Dermatology, Venereology, and Allergology, University Hospital Essen, Essen, Germany. 2 Medical Office Specialized on Diabetology, Stadithergen, Germany. 3 Medical Office Specialized on Vascular Medicine, Köln, Germany. 4 Medical Office Specialized on Phiebology, Würzburg, Germany. 5 Medical Office Specialized on Internal Medicine, Kornwestheim, Germany. 6 URGO Gmithl, Subtbach, Germany. 7 Medical Affairs Department, Laboratories URGO Medical, Paris, France. 8 Medical Office Specialized on Phiebology, Hamburg, Germany.

THE LARGEST OBSERVATIONAL STUDY EVER CONDUCTED FOR A SILVER DRESSING!

THIS ARTICLE IS REPRINTED FROM THE JOURNAL OF WOUND CARE VOL 29, NO 3, MARCH 2





Real life evidence: effectively reduces levels of exudate

Proportion of wounds infected/at risk of infection in caseload with high/moderate level of exudate

Chronic Wounds

(eg. Diabetic foot ulcers, Leg ulcers, pressure ulcers)

54%

33%

16%

Acute Wounds

(eg. Trauma wounds, Burns, Post-op)



14%

3%



UrgoClean Ag effectively reduces the level of exudate (**70% reduction**), in line with the reduction of clinical signs of infection



Real life evidence: effectively treats UrgoClean Ag infected wounds and clinical signs of local infection

Proportion of diagnosed infected wounds in caseload

Chronic Wounds

(eg. Diabetic foot ulcers, Leg ulcers, pressure ulcers)



WEEK 2

WEEK 3

Acute Wounds

(eg. Trauma wounds, Burns, Post-op)



WEEK 2

WEEK 3

UrgoClean Ag demonstrates effectiveness by significantly reducing the number of diagnosed infected woundsand the clinical signs of local infection after only 2 weeks





When looking at antimicrobials, which of these criteria are most important to you?

Fighting the visible and invisible enemies









Percentage of nurses who found UrgoClean Ag performed better than a silver containing CMC dressing

Ensuring patient comfort and adherence









Allowing easy integration in your standard of care

















UrgoClean Ag in clinical practice

How long currently does it take to treat your infected wounds/at risk of infection?

LEG ULCER







VENOUS LEG ULCER









UrgoClean Ag in clinical practice

How long currently does it take to treat your infected wounds/at risk of infection?

DIABETIC FOOT ULCER





DIABETIC FOOT ULCER









UrgoClean Ag in clinical practice

How long currently does it take to treat your infected wounds/at risk of infection?

TRAUMATIC WOUND







BURN WOUND









Easy to integrate into your infection management practice

UrgoClean Ag is suitable for ALL wounds at risk or with signs of local infection

Risk of infection & local infection

UrgoClean Ag

3iofiln

Spreading infection

UrgoClean Ag

+ Systemic Antibiotics

Systemic infection

UrgoClean Ag

+ Systemic Antibiotics



SIZES

6 x 6cm

10 x 10cm

15 x 20cm







used with a secondary



Can be cut



Can be used under compression



dressing

can be used in a cavity wound when cut in a spiral



removal







SIMPLE

Suitable for patients who self-care: can stay in place for up to 7 days.

SAFE

Safe & easy to use with 1-step application process.

No pain at dressing changes.

EFFECTIVE

Fast, effective reduction of local signs of infection

Minimises infection recurrence by complete and continuous cleaning action in the removal of slough, exudate, biofilms and debris from the wound.





How confident are you that UrgoClean Ag can help you return your patients to healing?

Have you struggled to heal wounds like these in your caseload?

Which of your current patients could benefit from UrgoClean Ag?









FOR MORE

INFORMATION

CONTACT URGO MEDICAL



www.urgomedical.co.uk/contact






DOWNLOAD

YOUR

CERTIFICATE



www.jcn-live.co.uk/virtual-lunch-meeting